ArticleNutrients2025
Supplementation with hArg During the Rapid Growth of the Placenta Modulates Final Placental Angiogenesis and Pregnancy Outcomes.
Article in Nutrients, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundPlacental angiogenesis is crucial for ensuring placental function and normal fetal development. It has been demonstrated that elevated plasma levels of homoarginine (hArg), an endogenous amino acid, during pregnancy correlate with enhanced vascular endothelial function. However, the effect of hArg in placental angiogenesis during pregnancy is still ambiguous. This study seeks to evaluate the impact of supplemental hArg during the rapid placental growth phase in early pregnancy, a key moment for placental angiogenesis, on ultimate pregnancy outcomes and placental angiogenesis in rats, as well as its potential processes.
methodsThis study utilized thirty 8-week-old female Sprague Dawley rats as pregnant animals, which were randomly allocated to control and treatment groups (15 per group) and administered 20 mg/kg of hArg from embryonic day 0.5 (E0.5) to E13. The dams were euthanized on E21.
resultsMaternal hArg dietary supplementation positively influenced pregnancy outcomes, resulting in a significant increase in the number of live-born offspring and total placental weight, alongside elevated maternal circulating reproductive hormone levels. Additionally, the upregulation of the amino acid transporter in the placenta of the treatment group established a basis for hArg accumulation in the placenta, hence promoting hArg-specific augmentation of eNOS-mediated NO production. The treated group simultaneously demonstrated an expanded labyrinthine zone, increased blood sinusoids area, enhanced vascular density, and raised levels of proangiogenic factors. Mechanistically, hArg enhanced the expression of proteins linked with the PI3K/AKT signaling pathway.
conclusionsSupplementation with hArg during the placenta's rapid growth phase enhances placental angiogenesis, ultimately enhancing pregnancy outcomes. This effect may be attributed to the regulation of the PI3K/AKT signaling pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.